211 related articles for article (PubMed ID: 29296529)
21. Engineered Biomimetic Copper Sulfide Nanozyme Mediates "Don't Eat Me" Signaling for Photothermal and Chemodynamic Precision Therapies of Breast Cancer.
Zhan Z; Zeng W; Liu J; Zhang L; Cao Y; Li P; Ran H; Wang Z
ACS Appl Mater Interfaces; 2023 May; 15(20):24071-24083. PubMed ID: 37159843
[TBL] [Abstract][Full Text] [Related]
22. Breaking the 'don't eat me' signal: in silico design of CD47-directed peptides for cancer immunotherapy.
Laddha K; Sobhia ME
Mol Divers; 2023 Sep; ():. PubMed ID: 37759140
[TBL] [Abstract][Full Text] [Related]
23. CD47 (don't eat me signal) expression levels and its relationship with clinicopathologic features in early-stage prostate carcinoma.
Semiz HS; Küçük Ü; Kısa E; Keskinkılıç M; Süyün DE; Arayıcı ME; Atağ E; Karaoglu A
Prostate; 2022 Dec; 82(16):1564-1571. PubMed ID: 36031743
[TBL] [Abstract][Full Text] [Related]
24. An Acquired and Endogenous Glycocalyx Forms a Bidirectional "Don't Eat" and "Don't Eat Me" Barrier to Phagocytosis.
Imbert PRC; Saric A; Pedram K; Bertozzi CR; Grinstein S; Freeman SA
Curr Biol; 2021 Jan; 31(1):77-89.e5. PubMed ID: 33096038
[TBL] [Abstract][Full Text] [Related]
25. A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer.
Betancur PA; Abraham BJ; Yiu YY; Willingham SB; Khameneh F; Zarnegar M; Kuo AH; McKenna K; Kojima Y; Leeper NJ; Ho P; Gip P; Swigut T; Sherwood RI; Clarke MF; Somlo G; Young RA; Weissman IL
Nat Commun; 2017 Apr; 8():14802. PubMed ID: 28378740
[TBL] [Abstract][Full Text] [Related]
26. The MHC class I-LILRB1 signalling axis as a promising target in cancer therapy.
Zhao J; Zhong S; Niu X; Jiang J; Zhang R; Li Q
Scand J Immunol; 2019 Nov; 90(5):e12804. PubMed ID: 31267559
[TBL] [Abstract][Full Text] [Related]
27. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target.
Barclay AN; Van den Berg TK
Annu Rev Immunol; 2014; 32():25-50. PubMed ID: 24215318
[TBL] [Abstract][Full Text] [Related]
28. A combined "eat me/don't eat me" strategy based on extracellular vesicles for anticancer nanomedicine.
Belhadj Z; He B; Deng H; Song S; Zhang H; Wang X; Dai W; Zhang Q
J Extracell Vesicles; 2020 Aug; 9(1):1806444. PubMed ID: 32944191
[TBL] [Abstract][Full Text] [Related]
29. Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release.
Lian S; Xie R; Ye Y; Xie X; Li S; Lu Y; Li B; Cheng Y; Katanaev VL; Jia L
EBioMedicine; 2019 Apr; 42():281-295. PubMed ID: 30878596
[TBL] [Abstract][Full Text] [Related]
30. Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals.
McCracken MN; Cha AC; Weissman IL
Clin Cancer Res; 2015 Aug; 21(16):3597-601. PubMed ID: 26116271
[TBL] [Abstract][Full Text] [Related]
31. Diffuse malignant mesothelioma.
Oviedo SP; Cagle PT
Arch Pathol Lab Med; 2012 Aug; 136(8):882-8. PubMed ID: 22849735
[TBL] [Abstract][Full Text] [Related]
32. Characterization of cluster of differentiation 47 expression and its potential as a therapeutic target in esophageal squamous cell cancer.
Zhao CL; Yu S; Wang SH; Li SG; Wang ZJ; Han SN
Oncol Lett; 2018 Feb; 15(2):2017-2023. PubMed ID: 29399202
[TBL] [Abstract][Full Text] [Related]
33. CD47 in Erythrocyte Ageing and Clearance - the Dutch Point of View.
Burger P; de Korte D; van den Berg TK; van Bruggen R
Transfus Med Hemother; 2012 Oct; 39(5):348-52. PubMed ID: 23801927
[TBL] [Abstract][Full Text] [Related]
34. The BALB/c-specific polymorphic SIRPA enhances its affinity for human CD47, inhibiting phagocytosis against human cells to promote xenogeneic engraftment.
Iwamoto C; Takenaka K; Urata S; Yamauchi T; Shima T; Kuriyama T; Daitoku S; Saito Y; Miyamoto T; Iwasaki H; Kitabayashi I; Itoh K; Kishimoto J; Kohda D; Matozaki T; Akashi K
Exp Hematol; 2014 Mar; 42(3):163-171.e1. PubMed ID: 24269920
[TBL] [Abstract][Full Text] [Related]
35. BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma.
Liu F; Jiang CC; Yan XG; Tseng HY; Wang CY; Zhang YY; Yari H; La T; Farrelly M; Guo ST; Thorne RF; Jin L; Wang Q; Zhang XD
Oncotarget; 2017 Sep; 8(41):69477-69492. PubMed ID: 29050218
[TBL] [Abstract][Full Text] [Related]
36. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
37. A Glutamine-Rich Carrier Efficiently Delivers Anti-CD47 siRNA Driven by a "Glutamine Trap" To Inhibit Lung Cancer Cell Growth.
Wu J; Li Z; Yang Z; Guo L; Zhang Y; Deng H; Wang C; Feng M
Mol Pharm; 2018 Aug; 15(8):3032-3045. PubMed ID: 29939755
[TBL] [Abstract][Full Text] [Related]
38. Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives.
Ye ZH; Yu WB; Huang MY; Chen J; Lu JJ
Acta Pharm Sin B; 2023 Apr; 13(4):1467-1487. PubMed ID: 37139405
[TBL] [Abstract][Full Text] [Related]
39. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.
Piccione EC; Juarez S; Tseng S; Liu J; Stafford M; Narayanan C; Wang L; Weiskopf K; Majeti R
Clin Cancer Res; 2016 Oct; 22(20):5109-5119. PubMed ID: 27126995
[TBL] [Abstract][Full Text] [Related]
40. Pleural mesothelioma.
Ruffie P
Curr Opin Oncol; 1992 Apr; 4(2):334-41. PubMed ID: 1591306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
